Aspire Biopharma Holdings Inc (ASBP)

$6.05 +0.21 (3.60%)
Market Cap 7.80M
Revenue (ttm) 10,000.00
Net Income (ttm) -24.48M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -244,800.00%
Debt to Equity Ratio 0.00
Volume 66,800
Avg Vol 704,587
Day's Range N/A - N/A
Shares Out 1.30M
Stochastic %K 92%
Beta 0.17
Analysts Strong Buy
Price Target N/A

Company Profile

Aspire Biopharma Holdings, Inc., an early-stage biopharmaceutical company, develops and markets disruptive technology for novel sublingual delivery mechanisms in the United States. It offers sublingual aspirin product that is a soluble, PH neutral, and fast acting aspirin, which addresses cardiology emergencies and pain management. The company is also developing formulations for sublingually administered products, such as melatonin sleep-aid product; vitamins D, E, and K; testosterone; and semag...

Industry: Biotechnology
Sector: Healthcare
Phone: 908 987 3002
Address:
23150 Fashion Drive, Suite 232, Estero, United States
Arnie_510
Arnie_510 Jun. 4 at 8:47 PM
$ASBP Someone said dark-money scam. Anyone here know anything about that? Oneway trip into their coffers, while the SEC turns a blind eye? I’m not sure, but they’ve pretty much cornered the market on reverse stock splits and they don’t even have a real office/facility/headquarters, just a virtual mailing address location. DYOR prior to becoming a victim like so many others.
0 · Reply
Arnie_510
Arnie_510 Jun. 4 at 2:51 PM
$ASBP I can’t believe this SCAM is still trading.
0 · Reply
Evilalchemist
Evilalchemist Jun. 4 at 1:42 PM
$ASBP wait for the warrants to be exercised it will be back at .04 cents dilution imbound
0 · Reply
supplySHOCK
supplySHOCK Jun. 4 at 10:50 AM
$DKI $ASBP $AIXI $OLOX assist
1 · Reply
supplySHOCK
supplySHOCK Jun. 4 at 10:14 AM
$DKI $ASBP $PAVM $MTEX merch
0 · Reply
supplySHOCK
supplySHOCK Jun. 4 at 8:23 AM
$DKI $ASBP $AIXI $OLOX sharing
0 · Reply
Arnie_510
Arnie_510 Jun. 4 at 12:04 AM
$ASBP This cash funnel should be renamed 𝗥𝗲𝘃𝗲𝗿𝘀𝗲 𝗦𝘁𝗼𝗰𝗸 𝗦𝗽𝗹𝗶𝘁𝘀 𝗜𝗻𝗰. is more fitting, nothing more than a corporate ATM machine.
0 · Reply
supplySHOCK
supplySHOCK Jun. 3 at 9:37 PM
$PASG $BULL $DKI $ASBP notes
0 · Reply
Arnie_510
Arnie_510 Jun. 3 at 6:30 PM
$ASBP Huge Pile of Shit
0 · Reply
Evilalchemist
Evilalchemist Jun. 3 at 1:40 PM
$ASBP nothing like it this is the biggest pile of shit ever
0 · Reply
Latest News on ASBP
Aspire Biopharma issues letter to shareholders

2026-05-28T15:44:39.000Z - 7 days ago

Aspire Biopharma issues letter to shareholders

Aspire Biopharma Issues Shareholder Letter

May 28, 2026, 8:30 AM EDT - 7 days ago

Aspire Biopharma Issues Shareholder Letter

Aspire Biopharma’s Buzz Bomb partners with EoS Fitness

2026-05-27T13:26:22.000Z - 8 days ago

Aspire Biopharma’s Buzz Bomb partners with EoS Fitness

Aspire Biopharma's BUZZ BOMBTM Partners with EoS Fitness to Empower High-Performance Lifestyles for Millions of Members

May 27, 2026, 8:30 AM EDT - 8 days ago

Aspire Biopharma's BUZZ BOMBTM Partners with EoS Fitness to Empower High-Performance Lifestyles for Millions of Members

Aspire Biopharma Holdings Inc trading halted, news pending

2026-05-08T23:50:15.000Z - 27 days ago

Aspire Biopharma Holdings Inc trading halted, news pending

Aspire Biopharma to effect 1-for-30 reverse stock split

2026-05-07T17:59:49.000Z - 4 weeks ago

Aspire Biopharma to effect 1-for-30 reverse stock split

Aspire Biopharma Holdings, Inc. Announces Approval Of Reverse Stock Split Ratio

May 7, 2026, 11:00 AM EDT - 4 weeks ago

Aspire Biopharma Holdings, Inc. Announces Approval Of Reverse Stock Split Ratio

Aspire Biopharma announces $5M share repurchase plan

2026-04-27T12:40:32.000Z - 5 weeks ago

Aspire Biopharma announces $5M share repurchase plan

Aspire Biopharma Announces $5.0 Million Share Repurchase Program

Apr 27, 2026, 8:30 AM EDT - 5 weeks ago

Aspire Biopharma Announces $5.0 Million Share Repurchase Program

Aspire Biopharma closes final tranche of $21M private placement

2026-04-20T14:15:12.000Z - 6 weeks ago

Aspire Biopharma closes final tranche of $21M private placement

Aspire Biopharma Announces Closing of Second and Final Tranche of $21 Million Private Placement by Select Investors; Secures Commitment Letter for $22.5M Credit Facility to Fund the DCS Acquisition

Apr 20, 2026, 8:30 AM EDT - 6 weeks ago

Aspire Biopharma Announces Closing of Second and Final Tranche of $21 Million Private Placement by Select Investors; Secures Commitment Letter for $22.5M Credit Facility to Fund the DCS Acquisition

Buzz Bomb brand ambassador to attempt fastest 100-mile treadmill run

2026-04-17T12:15:44.000Z - 6 weeks ago

Buzz Bomb brand ambassador to attempt fastest 100-mile treadmill run

Aspire Biopharma's Buzz Bomb(TM) Caffeine Company's Brand Ambassador, Ashley Paulson, to Attempt Fastest 100-Mile Treadmill Run at 2026 Boston Marathon Expo

Apr 17, 2026, 8:00 AM EDT - 6 weeks ago

Aspire Biopharma's Buzz Bomb(TM) Caffeine Company's Brand Ambassador, Ashley Paulson, to Attempt Fastest 100-Mile Treadmill Run at 2026 Boston Marathon Expo

Aspire Biopharma enters LOI to acquire Dura Driver Control Systems for $30M

2026-04-16T12:48:21.000Z - 7 weeks ago

Aspire Biopharma enters LOI to acquire Dura Driver Control Systems for $30M

Aspire Biopharma Has Entered Into a Letter of Intent to Acquire a Leading Global Automotive Supplier With a 100+ Year History and $200M+ in 2025 Revenue

Apr 16, 2026, 8:30 AM EDT - 7 weeks ago

Aspire Biopharma Has Entered Into a Letter of Intent to Acquire a Leading Global Automotive Supplier With a 100+ Year History and $200M+ in 2025 Revenue

Aspire Biopharma subsidiary announce sales, marketing agreement with Interwest

2026-04-15T12:22:20.000Z - 7 weeks ago

Aspire Biopharma subsidiary announce sales, marketing agreement with Interwest

Aspire Biopharma's Buzz Bomb Caffeine Company Partners with Interwest Brokerage to Accelerate Retail Expansion

Apr 15, 2026, 8:00 AM EDT - 7 weeks ago

Aspire Biopharma's Buzz Bomb Caffeine Company Partners with Interwest Brokerage to Accelerate Retail Expansion

Aspire Biopharma subsidiary signs retail distribution agreement with TruLife

2026-03-19T12:57:13.000Z - 2 months ago

Aspire Biopharma subsidiary signs retail distribution agreement with TruLife

Aspire Biopharma's Subsidiary Announces Agreement with TruLife Distribution to Drive National Retail Expansion

Mar 19, 2026, 8:00 AM EDT - 2 months ago

Aspire Biopharma's Subsidiary Announces Agreement with TruLife Distribution to Drive National Retail Expansion

Aspire Biopharma's Subsidiary, Buzz Bomb Caffeine Company, Appoints John Choe as Western Sales Director

Mar 17, 2026, 8:30 AM EDT - 2 months ago

Aspire Biopharma's Subsidiary, Buzz Bomb Caffeine Company, Appoints John Choe as Western Sales Director

Aspire Biopharma's Subsidiary to Feature BUZZ BOMB(TM) at The Health & Fitness Show 2026

Mar 12, 2026, 8:00 AM EDT - 3 months ago

Aspire Biopharma's Subsidiary to Feature BUZZ BOMB(TM) at The Health & Fitness Show 2026

Aspire Biopharma launches BUZZ BOMB Covenience Store Pack

2026-03-10T12:51:37.000Z - 3 months ago

Aspire Biopharma launches BUZZ BOMB Covenience Store Pack

Aspire Biopharma's BUZZ BOMB(TM) Disrupts Energy Category with New Convenience Store Pack

Mar 10, 2026, 8:30 AM EDT - 3 months ago

Aspire Biopharma's BUZZ BOMB(TM) Disrupts Energy Category with New Convenience Store Pack

Aspire Biopharma, Microsize partner for sublingual alprazolam formulation

2026-03-03T13:30:58.000Z - 3 months ago

Aspire Biopharma, Microsize partner for sublingual alprazolam formulation

Aspire Biopharma Partners with Microsize to Develop Rapid-delivery Sublingual Powder Formulation of Alprazolam for Faster Anxiety Relief

Mar 3, 2026, 8:00 AM EST - 3 months ago

Aspire Biopharma Partners with Microsize to Develop Rapid-delivery Sublingual Powder Formulation of Alprazolam for Faster Anxiety Relief

Aspire Biopharma’s Buzz Bomb announces expansion of social media footprint

2026-02-25T14:02:56.000Z - 3 months ago

Aspire Biopharma’s Buzz Bomb announces expansion of social media footprint

Aspire Biopharma's Buzz Bomb(TM) Caffeine Company Achieves Record Social Media Growth and Sales Surge Following World-Record Marathon Sponsorship

Feb 25, 2026, 8:30 AM EST - 3 months ago

Aspire Biopharma's Buzz Bomb(TM) Caffeine Company Achieves Record Social Media Growth and Sales Surge Following World-Record Marathon Sponsorship

Aspire Biopharma regains compliance with Nasdaq listing requirements

2026-02-20T13:05:16.000Z - 3 months ago

Aspire Biopharma regains compliance with Nasdaq listing requirements

Aspire Biopharma Regains Full Compliance with Nasdaq Listing Requirements

Feb 20, 2026, 8:00 AM EST - 3 months ago

Aspire Biopharma Regains Full Compliance with Nasdaq Listing Requirements

Aspire Biopharma's Buzz Bomb Caffeine Company Names ChicExecs as Public Relations Agency of Record

Feb 19, 2026, 8:00 AM EST - 3 months ago

Aspire Biopharma's Buzz Bomb Caffeine Company Names ChicExecs as Public Relations Agency of Record

Aspire Biopharma files to sell 159.1M shares of common stock for holders

2026-02-17T21:25:29.000Z - 3 months ago

Aspire Biopharma files to sell 159.1M shares of common stock for holders

Aspire Biopharma files provisional patent application for Meclizine formulation

2026-02-17T13:51:22.000Z - 3 months ago

Aspire Biopharma files provisional patent application for Meclizine formulation

Aspire Biopharma Files Provisional Patent Application for a Fast-Acting Sublingual Powder Formulation of Meclizine (Generic Dramamine(R))

Feb 17, 2026, 8:30 AM EST - 3 months ago

Aspire Biopharma Files Provisional Patent Application for a Fast-Acting Sublingual Powder Formulation of Meclizine (Generic Dramamine(R))

Aspire Biopharma appoints Phillip Balatsos to board of directors

2026-02-13T13:10:38.000Z - 3 months ago

Aspire Biopharma appoints Phillip Balatsos to board of directors

Aspire Biopharma Announces the Appointment of New Member to Its Board of Directors

Feb 13, 2026, 8:00 AM EST - 3 months ago

Aspire Biopharma Announces the Appointment of New Member to Its Board of Directors

Aspire Biopharma files patent application for sublingual ondansetron formulation

2026-02-12T13:38:49.000Z - 4 months ago

Aspire Biopharma files patent application for sublingual ondansetron formulation

Aspire Biopharma Files Provisional Patent Application for a Fast-Acting Sublingual Powder Formulation of Ondansetron (Generic Zofran(R))

Feb 12, 2026, 8:00 AM EST - 4 months ago

Aspire Biopharma Files Provisional Patent Application for a Fast-Acting Sublingual Powder Formulation of Ondansetron (Generic Zofran(R))

Aspire Biopharma Announces $21 Million Private Placement by Select Investors, Strengthening Balance Sheet, Capital Position, and Fortifying Shareholder Equity to Meet Nasdaq Requirements

Feb 11, 2026, 7:45 AM EST - 4 months ago

Aspire Biopharma Announces $21 Million Private Placement by Select Investors, Strengthening Balance Sheet, Capital Position, and Fortifying Shareholder Equity to Meet Nasdaq Requirements

Aspire Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

Feb 10, 2026, 8:00 AM EST - 4 months ago

Aspire Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

Aspire Biopharma's Wholly Owned Subsidiary, Buzz Bomb Caffeine Company, to Showcase BUZZ BOMB(TM) Caffeine and its Innovative Sublingual Delivery Technology at The Sports & Active Nutrition Summit

Feb 5, 2026, 8:00 AM EST - 4 months ago

Aspire Biopharma's Wholly Owned Subsidiary, Buzz Bomb Caffeine Company, to Showcase BUZZ BOMB(TM) Caffeine and its Innovative Sublingual Delivery Technology at The Sports & Active Nutrition Summit

Aspire Biopharma's Wholly Owned Subsidiary, Buzz Bomb Caffeine Company, Partners with Blue Shark Beverages to Expand Southern California Distribution

Feb 3, 2026, 8:00 AM EST - 4 months ago

Aspire Biopharma's Wholly Owned Subsidiary, Buzz Bomb Caffeine Company, Partners with Blue Shark Beverages to Expand Southern California Distribution

Aspire Biopharma Secures Agreement with Microsize for Development of Novel Sublingual Aspirin

Jan 29, 2026, 8:00 AM EST - 4 months ago

Aspire Biopharma Secures Agreement with Microsize for Development of Novel Sublingual Aspirin

Aspire Biopharma Files Provisional Patent Application for Industry-First Sublingual Powder Formulation of Clopidogrel (Generic Plavix(R)) to Address Gastric Bleeding Risks

Jan 27, 2026, 8:00 AM EST - 4 months ago

Aspire Biopharma Files Provisional Patent Application for Industry-First Sublingual Powder Formulation of Clopidogrel (Generic Plavix(R)) to Address Gastric Bleeding Risks

Aspire Biopharma Scales Consumer Division with Delivery of Two Million BUZZ BOMB(TM) Units Featuring Modernized Brand Identity

Jan 22, 2026, 8:00 AM EST - 4 months ago

Aspire Biopharma Scales Consumer Division with Delivery of Two Million BUZZ BOMB(TM) Units Featuring Modernized Brand Identity

Aspire Biopharma's Unveils Bold New Era for BUZZ BOMB(TM) Caffeine with Dynamic Website and Packaging Redesign

Jan 21, 2026, 8:00 AM EST - 4 months ago

Aspire Biopharma's Unveils Bold New Era for BUZZ BOMB(TM) Caffeine with Dynamic Website and Packaging Redesign

Aspire Biopharma Files Provisional Patent Application for Industry-First Sublingual Formulation of Alprazolam - Generic Xanax(R) - for Rapid Anxiety Relief

Jan 20, 2026, 8:00 AM EST - 4 months ago

Aspire Biopharma Files Provisional Patent Application for Industry-First Sublingual Formulation of Alprazolam - Generic Xanax(R) - for Rapid Anxiety Relief

Aspire Biopharma Announces Reverse Stock Split

Jan 14, 2026, 8:00 AM EST - 5 months ago

Aspire Biopharma Announces Reverse Stock Split

Aspire Biopharma Announces Successful Pre-IND Meeting with FDA for High-Dose Sublingual Aspirin (OTASA)

Jan 7, 2026, 8:00 AM EST - 5 months ago

Aspire Biopharma Announces Successful Pre-IND Meeting with FDA for High-Dose Sublingual Aspirin (OTASA)

Aspire Biopharma Welcomes Elite Ultra-Runner Ashley Paulson as Global Brand Ambassador for BUZZ BOMB(R) Caffeine

Dec 18, 2025, 8:30 AM EST - 6 months ago

Aspire Biopharma Welcomes Elite Ultra-Runner Ashley Paulson as Global Brand Ambassador for BUZZ BOMB(R) Caffeine

Aspire Biopharma Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements

Dec 12, 2025, 5:00 PM EST - 6 months ago

Aspire Biopharma Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements

Aspire Biopharma Provides Q3 2025 Business Update

Dec 4, 2025, 9:00 AM EST - 6 months ago

Aspire Biopharma Provides Q3 2025 Business Update

Aspire Biopharma Submits Pre-IND Meeting Request and Briefing Package to U.S. FDA for Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)

Dec 2, 2025, 9:00 AM EST - 6 months ago

Aspire Biopharma Submits Pre-IND Meeting Request and Briefing Package to U.S. FDA for Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)

Aspire BioPharma Welcomes Dr. Mark J. Jaroszeski as New Scientific Team Member

Nov 26, 2025, 9:00 AM EST - 6 months ago

Aspire BioPharma Welcomes Dr. Mark J. Jaroszeski as New Scientific Team Member

Aspire Biopharma Engages with Global Pharmaceutical Leaders at CPHI Frankfurt to Advance Partnership Discussions for its Sublingual High-Dose Aspirin

Nov 6, 2025, 9:00 AM EST - 7 months ago

Aspire Biopharma Engages with Global Pharmaceutical Leaders at CPHI Frankfurt to Advance Partnership Discussions for its Sublingual High-Dose Aspirin

Aspire Biopharma Holdings, Inc. Announces Filing of Omnibus Patent Application for Its Innovative Sublingual Drug Delivery Platform

Oct 6, 2025, 8:30 AM EDT - 8 months ago

Aspire Biopharma Holdings, Inc. Announces Filing of Omnibus Patent Application for Its Innovative Sublingual Drug Delivery Platform

Aspire Biopharma to Present at Noble Capital Markets 2025 Emerging Growth Virtual Equity Conference - October 8-9, 2025

Oct 3, 2025, 11:30 AM EDT - 8 months ago

Aspire Biopharma to Present at Noble Capital Markets 2025 Emerging Growth Virtual Equity Conference - October 8-9, 2025

Aspire Biopharma Announces Milestone Roadmap Targeting H2 2025 FDA Submission for Sublingual Aspirin and Key 2026 Milestones for Needle-Free Semaglutide (Diabetes, Weight Management) and more-rapid ED medication

Oct 1, 2025, 8:30 AM EDT - 8 months ago

Aspire Biopharma Announces Milestone Roadmap Targeting H2 2025 FDA Submission for Sublingual Aspirin and Key 2026 Milestones for Needle-Free Semaglutide (Diabetes, Weight Management) and more-rapid ED medication

Aspire Biopharma Engages Well-Known Athletes and Influencers to Accelerate Consumer Awareness and Sales of its BUZZ BOMB(TM) Sublingual Caffeine Pre-Workout Product

Sep 17, 2025, 8:30 AM EDT - 9 months ago

Aspire Biopharma Engages Well-Known Athletes and Influencers to Accelerate Consumer Awareness and Sales of its BUZZ BOMB(TM) Sublingual Caffeine Pre-Workout Product

Aspire Biopharma Announces Initial Production Order of Two Million Servings (100,000 20-packs) of BUZZ BOMB(TM) Pre-Workout Supplement

Sep 16, 2025, 8:30 AM EDT - 9 months ago

Aspire Biopharma Announces Initial Production Order of Two Million Servings (100,000 20-packs) of BUZZ BOMB(TM) Pre-Workout Supplement

Aspire Biopharma Announces Breakthrough Final Results from Clinical Trial of Investigational New Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)

Sep 3, 2025, 8:30 AM EDT - 9 months ago

Aspire Biopharma Announces Breakthrough Final Results from Clinical Trial of Investigational New Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)

Aspire Biopharma Announces Positive Top-Line Results from Clinical Trial of Investigational New Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)

Aug 18, 2025, 8:30 AM EDT - 10 months ago

Aspire Biopharma Announces Positive Top-Line Results from Clinical Trial of Investigational New Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)

Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference August 20

Aug 14, 2025, 8:00 AM EDT - 10 months ago

Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference August 20

Aspire Biopharma Successfully Launches BUZZ BOMB(TM) Pre-Workout Supplement at FitCon and FitExpo, Two of the Largest Fitness Conventions in the World

Aug 13, 2025, 9:10 AM EDT - 10 months ago

Aspire Biopharma Successfully Launches BUZZ BOMB(TM) Pre-Workout Supplement at FitCon and FitExpo, Two of the Largest Fitness Conventions in the World

Aspire Biopharma Holdings, Inc. Unveils E-commerce Platform, Launches with its BUZZ BOMB Pre-Workout Supplement

Jul 31, 2025, 8:30 AM EDT - 11 months ago

Aspire Biopharma Holdings, Inc. Unveils E-commerce Platform, Launches with its BUZZ BOMB Pre-Workout Supplement

Aspire Biopharma Holdings, Inc. Announces CEO Transition

Jul 30, 2025, 7:45 PM EDT - 11 months ago

Aspire Biopharma Holdings, Inc. Announces CEO Transition

Aspire Biopharma Holdings, Inc. to Launch its BUZZ BOMB Pre-Workout Supplement at FitCon and FitExpo, Two of the Largest Fitness Conventions in the World

Jul 22, 2025, 10:45 AM EDT - 11 months ago

Aspire Biopharma Holdings, Inc. to Launch its BUZZ BOMB Pre-Workout Supplement at FitCon and FitExpo, Two of the Largest Fitness Conventions in the World

Aspire Biopharma Holdings, Inc., Announces Positive Consumer Feedback from Company Sampling of BUZZ BOMB(TM), its New Sublingual Pre-Workout Supplement

Jul 9, 2025, 8:30 AM EDT - 11 months ago

Aspire Biopharma Holdings, Inc., Announces Positive Consumer Feedback from Company Sampling of BUZZ BOMB(TM), its New Sublingual Pre-Workout Supplement

Aspire Biopharma Holdings, Inc., Announces Last Patient Dosed in Phase 1 Clinical Trial of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation

Jun 24, 2025, 8:30 AM EDT - 1 year ago

Aspire Biopharma Holdings, Inc., Announces Last Patient Dosed in Phase 1 Clinical Trial of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation

Arnie_510
Arnie_510 Jun. 4 at 8:47 PM
$ASBP Someone said dark-money scam. Anyone here know anything about that? Oneway trip into their coffers, while the SEC turns a blind eye? I’m not sure, but they’ve pretty much cornered the market on reverse stock splits and they don’t even have a real office/facility/headquarters, just a virtual mailing address location. DYOR prior to becoming a victim like so many others.
0 · Reply
Arnie_510
Arnie_510 Jun. 4 at 2:51 PM
$ASBP I can’t believe this SCAM is still trading.
0 · Reply
Evilalchemist
Evilalchemist Jun. 4 at 1:42 PM
$ASBP wait for the warrants to be exercised it will be back at .04 cents dilution imbound
0 · Reply
supplySHOCK
supplySHOCK Jun. 4 at 10:50 AM
$DKI $ASBP $AIXI $OLOX assist
1 · Reply
supplySHOCK
supplySHOCK Jun. 4 at 10:14 AM
$DKI $ASBP $PAVM $MTEX merch
0 · Reply
supplySHOCK
supplySHOCK Jun. 4 at 8:23 AM
$DKI $ASBP $AIXI $OLOX sharing
0 · Reply
Arnie_510
Arnie_510 Jun. 4 at 12:04 AM
$ASBP This cash funnel should be renamed 𝗥𝗲𝘃𝗲𝗿𝘀𝗲 𝗦𝘁𝗼𝗰𝗸 𝗦𝗽𝗹𝗶𝘁𝘀 𝗜𝗻𝗰. is more fitting, nothing more than a corporate ATM machine.
0 · Reply
supplySHOCK
supplySHOCK Jun. 3 at 9:37 PM
$PASG $BULL $DKI $ASBP notes
0 · Reply
Arnie_510
Arnie_510 Jun. 3 at 6:30 PM
$ASBP Huge Pile of Shit
0 · Reply
Evilalchemist
Evilalchemist Jun. 3 at 1:40 PM
$ASBP nothing like it this is the biggest pile of shit ever
0 · Reply
Capark12
Capark12 Jun. 2 at 7:55 PM
$ASBP Everytime I debate selling. My gut tells me to stick it out. It wouldn’t take much to get this to 20+
0 · Reply
Arnie_510
Arnie_510 Jun. 2 at 7:54 PM
$ASBP Yes Sir I agree
0 · Reply
Arnie_510
Arnie_510 Jun. 2 at 7:53 PM
$ASBP Manipulated Garbage They survive off of reverse stock splits and suckers who dream about hitting it big. Meanwhile, they sell/dilute to keep the cash flowing in. The SEC is worthless, it’s as if they deliberately look the other way. Say hello to your money!
0 · Reply
Leo70o
Leo70o Jun. 2 at 5:18 PM
$ASBP If this stock was a real person, I would’ve kidnapped it tied it to a chair in a dark room, and every single time it drops a point. I’d slap the living daylights out of it I’d choke it for a bit, drown it for a bit. a whole cocktail of torture that’d make it regret the day it ever went public
0 · Reply
METS1
METS1 Jun. 1 at 6:53 PM
$ASBP I was wrong for the proxy vote meeting that's on June 8th. They was no mention of a R/S they. I told you if I was wrong I omit to it. If I not mistaken didn't the share holder voted and gave the board member they can do a R/S anytime.
1 · Reply
Capark12
Capark12 Jun. 1 at 5:19 PM
$ASBP lots of green right now
0 · Reply
gadgetmastertm
gadgetmastertm Jun. 1 at 5:17 PM
$ASBP do not FOMO. $HCWC jump in under $0.40. GLT
0 · Reply
Evilalchemist
Evilalchemist Jun. 1 at 2:50 PM
$ASBP trash
0 · Reply
Arnie_510
Arnie_510 May. 30 at 4:08 AM
$ASBP Bag Holder Over The Weekend Calls it Quits
0 · Reply
Psikus
Psikus May. 30 at 3:34 AM
$ASBP If you shirt this stock and if they really work on that sublingual aspirine that could save your life I don’t wish no one evil but one day you might wish that they have been successful and you might see all these dollars which you made on shorting it and just hear the paramedic that the regular aspirin didn’t act fast enough. And that might be the last words you will hear in this life. I just don’t know who you got to be that you try to destroy a pharmacy company? I don’t care if it’s a scam or not, what if it’s for real? Let it sink for a while, there is so many garbage companies that you can short. Have a blessed day.
0 · Reply
METS1
METS1 May. 29 at 10:41 PM
$ASBP I notice there are people that don't like the truth and hid behind it. I don't hid and I speak the truth and people don't like that too. Just look what all I have written. If I was wrong I admit to it and still others don't.
1 · Reply
METS1
METS1 May. 29 at 8:42 PM
$ASBP to Capark12 I didn't lose my rent money, since I owe my on house.
0 · Reply